When a promising biotech startup launches, it’s often years—and many millions of dollars invested—before anyone knows if their treatment is really going to work.
It’s been about two decades since virtual reality arrived as a major area for technically-adept tinkerers to explore. They’re still tinkering. But it’s a different story now: The arrival of the Oculus Rift, and its $2 billion vote of confidence from Facebook, suggests that VR is finally on a path to the mainstream.
Raising money is a huge part of being a CEO, but nothing can fully prepare you for the experience of taking your company public. Read More
This week Charles River Ventures, now known as CRV, announced that its new fund would make Silicon Valley the priority, formalizing a shift westward that has been going on for a few years now.